The latest biotech news

nash northsea therapeutics, liver disease, disease modeling

News and Trends 8 Jan 2020

NorthSea Therapeutics Raises €36M to Complete NASH Phase II Trial

The Dutch biotech NorthSea Therapeutics has raised a €36M ($40M) Series B round to fund the end of a phase IIb trial of its lead fatty acid drug to treat the liver condition NASH, as well as advancing two other drugs to clinical trials. There were two newcomers to the round: the US investor venBio […]

January 8, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2020

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix. Under the terms of the new agreement, the Chinese pharma will use Synaffix’s antibody-drug conjugate technology to develop a second drug for the treatment of cancer. No financial details were disclosed. Published 10/04/2019: Shanghai Miracogen will pay up to €111M […]

January 7, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jan 2020

AstraZeneca Recruits RNA Biotech to Develop Metabolic Disease Therapies

The UK biotech MiNA Therapeutics has launched a collaboration with AstraZeneca to develop small activating RNA drugs, which could treat metabolic diseases using targets unreachable by current medications. According to the agreement, the two partners will carry out preclinical research with the aim of generating candidate drugs based on small activating RNA, or saRNA — […]

January 7, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Jan 2020

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

A CAR T-cell therapy amplified by RNA technology, developed by BioNTech, has shown preclinical potential for tackling solid tumors, which are hard to treat with current CAR T-cell therapies. In a study published in Science, the CAR T-cell and RNA combination therapy suppressed tumors in mice implanted with human ovarian cancer for longer than regular […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

mutabilis novo holdings antibiotic resistance

News and Trends 6 Jan 2020

€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

Mutabilis has received a €5M investment from the Danish VC Novo Holdings’ REPAIR Impact Fund to fuel the development of a new class of antibiotics that could kill drug-resistant strains of gram-negative bacteria. The French company will use the money to advance one of its preclinical drugs, a wide-spectrum intravenous antibiotic, to clinical trials. The […]

January 6, 2020 - 2 minutesmins - By Jonathan Smith

News and Trends 3 Jan 2020

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

Update (03/01/2020): The global non-profit partnership CARB-X has awarded Antabio €4M ($4.4M) as a second grant installment funding development of a novel antibiotic for use against Pseudomonas infections in patients with cystic fibrosis. This is the second installment of a grant worth up to €7.6M awarded to Antabio in 2017. The French biotech was awarded […]

January 3, 2020 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Dec 2019

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

Berlin-based startup Legendairy Foods has raised €4M to develop cheese and other dairy products that have the same composition as milk but are not derived from animals. The fundraising was co-led by food tech investor Agronomics and M Ventures, the corporate venture capital arm of Merck. CPT Capital, an investor in alternative proteins, […]

December 20, 2019 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 20 Dec 2019

CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA

The German biotech CureVac has signed a deal potentially worth over €1B with Danish antibody developer Genmab to develop messenger RNA drugs that carry the instructions for therapeutic antibodies to be produced inside cancer patients. “We believe that the collaboration with Genmab represents the first antibody deal in the field of mRNA,” stated Daniel Menichella, […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

Update: First Ever Ebola Vaccine Gets US and EU Approval

Update (20/12/2019): After getting conditional approval in Europe in November, Merck has received FDA approval for its Ebola vaccine, the first to be approved in both regions. Published on 13/11/2019 The big pharma company Merck has won a conditional marketing authorization from the European Commission for the Ebola vaccine Ervebo, the first to be approved. […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 20 Dec 2019

Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost

The UK gene therapy biotech Freeline Therapeutics is to receive an investment worth €72M (£61.1M) from the UK VC firm Syncona in a Series C round to fund the clinical development of gene therapies for the blood disorder hemophilia B, Fabry disease, and other rare conditions. Of the €72M commitment, Syncona has already wired €36M […]

December 20, 2019 - 2 minutesmins - By Jonathan Smith

blood cancer disease model, multi-omics, CAR-T, oncology

News and Trends 18 Dec 2019

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers that have a mutation in the Notch pathway, a group of proteins that helps cells communicate with each other. Many cancers have mutations in these […]

December 18, 2019 - 2 minutesmins - By Helen Albert

News and Trends 17 Dec 2019

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Update (17/12/2019): Promethera has increased the total raised in its Series D round to €47.2M with the addition of new investors, including Innovation Growth Ventures and Pegasus Tech Ventures among others. The round will fund two ongoing clinical trials and the start of at least two new trials outside Europe. Published on 07/05/2019 The Belgian […]

December 17, 2019 - 2 minutesmins - By Jonathan Smith

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

NorthSea Therapeutics Raises €36M to Complete NASH Phase II Trial

Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug

AstraZeneca Recruits RNA Biotech to Develop Metabolic Disease Therapies

BioNTech’s RNA-Boosted CAR T-Cell Therapy Shrinks Tumors in Mice

€5M Investment to Fund French Biotech’s Resistance-Busting Antibiotic

Update: CARB-X Grants Antabio Additional €4M to Develop Cystic Fibrosis Antibiotic

German Startup Raises €4M Seed Round to Make Dairy Cheese Without Milk

CureVac and Genmab Team up to Make Antibody Cancer Drugs out of RNA

Update: First Ever Ebola Vaccine Gets US and EU Approval

Freeline’s Rare Disease Gene Therapies Get €72M Series C Boost

Cellestia Secures €18M to Develop First-in-Class Cancer Drug

Update: Cell Therapy Biotech Raises €47M to Fund NASH Clinical Trial

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!